IP Library Granted Patent US 11,166,965
Granted Patent B2
US 11,166,965 · App. 16/870,224 · Granted Nov 9, 2021

Compositions for use in stimulating bone growth

Inventors: Marie Noelle Horcajada (Echenevex, FR); Fanny Membrez (Cugy, CH); Elizabeth Offord Cavin (Montreux, CH)
Assignee: Societe des Produits Nestle S.A.
A61K31/593A23L33/155A23L33/16A61K31/05A61K31/351A61K31/592A61K31/7048A61K45/06A61K47/02A23V2002/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,166,965
App. No.
16/870,224
Granted
Nov 9, 2021
Kind
B2
Abstract

The present invention relates to use of a composition for maintenance of bone and/or cartilage health or prevention, alleviation and/or treatment of bone and/or cartilage disorders.

Claims (18)

1. A method of potentiating effects of oleuropein on bone formation and/or cartilage anabolism, the method comprising orally administering an effective amount of a composition consisting essentially of vitamin D and oleuropein to an individual in need thereof, wherein the effective amount of the composition comprises 800 to 1,200 IU of the Vitamin D, and the composition is administered to the individual at least once per day, for a time period of at least one month.

2. The method of claim 1 , wherein the effective amount of the composition comprises 850 to 1,000 IU of the Vitamin D.

3. The method of claim 1 , wherein the effective amount of the composition comprises 900 to 950 IU of the Vitamin D.

4. The method of claim 1 , wherein the effective amount of the composition comprises 0.01 mg to 1 g of the oleuropein.

5. The method of claim 1 , wherein the effective amount of the composition comprises 0.1 mg to 1 g of the oleuropein.

6. The method of claim 1 , wherein the effective amount of the composition comprises 1.0 mg to 1 g of the oleuropein.

7. The method of claim 1 , wherein the individual has a disorder linked to an imbalance in the relationship between bone formation and/or cartilage anabolism and bone resorption, and the effective amount of the composition potentiates stimulation of cartilage anabolism in the individual.

8. The method of claim 7 , wherein the disorder is osteoporosis.

9. The method of claim 1 , wherein the effective amount of the composition maintains and/or improves mobility in the individual.

10. A method of treatment and/or alleviation of a disorder linked to an imbalance in bone and/or cartilage metabolism, the method comprising orally administering an effective amount of a composition consisting essentially of Vitamin D and oleuropein to an individual having the disorder, wherein the effective amount of the composition comprises 800 to 1,200 IU of the Vitamin D, and the composition is administered to the individual at least once per day, for a time period of at least one month.

11. The method of claim 10 , wherein the effective amount of the composition comprises 850 to 1,000 IU of the Vitamin D.

12. The method of claim 10 , wherein the effective amount of the composition comprises 900 to 950 IU of the Vitamin D.

13. The method of claim 10 , wherein the effective amount of the composition comprises 0.01 mg to 1 g of the oleuropein.

14. The method of claim 10 , wherein the effective amount of the composition comprises 0.1 mg to 1 g of the oleuropein.

15. The method of claim 10 , wherein the effective amount of the composition comprises 1.0 mg to 1 g of the oleuropein.

16. The method of claim 10 , wherein the composition is a pharmaceutical composition consisting of the Vitamin D, the oleuropein and at least one excipient.

17. The method of claim 10 , wherein the disorder is osteoporosis.

18. The method of claim 10 , wherein the effective amount of the composition maintains and/or improves mobility in the individual.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 18, 2021
From: HORCAJADA, MARIE-NOELLE; MEMBREZ, FANNY; CAVIN, ELIZABETH OFFORD
To: NESTEC S.A.
Reel/Frame 056587/0109 →
MERGER Recorded Jun 18, 2021
From: NESTEC S.A.
To: SOCIETE DES PRODUITS NESTLE S.A.
Reel/Frame 056587/0171 →
Priority Claims (1)
EP 13162445 · Apr 5, 2013 · regional
Continuity (2)
Continuation 14780265
Related Publication 20200316094A1 · Oct 8, 2020